Dave Kappos Featured on “On Intellectual Property” Podcast
December 02, 2022
Cravath partner David J. Kappos was a featured guest on the November 29, 2022 episode of “On Intellectual Property,” a podcast series hosted by Nyemaster Goode. In the interview, Dave spoke about his career path as an in‑house attorney and working in the government and private practice, how intellectual property (“IP”) continues to inspire him and common misperceptions about the IP system. Dave also discussed the importance of a strong patent system, which plays a significant role in advancing innovation in the marketplace, technology and the healthcare industry, and some of the biggest threats to intellectual property in the United States.
Related Practices & Industries
People
- Photo
-
-
J.D., 1990, University of California, Berkeley, School of Law
-
B.S., 1983, University of California, Davissumma cum laude
- New York
- California
- District of Columbia
Education
Admitted In
Related News & Insights
Deals & Cases
November 07, 2022
Viatris’ Acquisitions of Oyster Point and Famy Life Sciences
On November 7, 2022, Viatris Inc. (“Viatris”), a global healthcare company, announced it intends to create an ophthalmology franchise by acquiring Oyster Point Pharma (“Oyster Point”) and Famy Life Sciences.
Deals & Cases
October 11, 2022
Brookfield Renewable and Cameco’s $7.875 Billion Acquisition of Westinghouse
On October 11, 2022, Brookfield Renewable Partners (“Brookfield Renewable”), together with its institutional partners and Cameco Corporation (“Cameco”), announced they are forming a strategic partnership (“the consortium”) to acquire Westinghouse Electric Company (“Westinghouse”), one of the world’s largest nuclear services businesses, for a total enterprise value of $7.875 billion.
Deals & Cases
August 08, 2022
Global Blood Therapeutics’ $5.4 Billion Acquisition by Pfizer
On August 8, 2022, Global Blood Therapeutics, Inc. (“GBT”), a biopharmaceutical company dedicated to the discovery, development and delivery of life‑changing treatments that provide hope to underserved patient communities, starting with sickle cell disease, and Pfizer Inc. (“Pfizer”) announced that the companies have entered into a definitive agreement under which Pfizer will acquire GBT. Under the terms of the transaction, Pfizer will acquire all the outstanding shares of GBT for $68.50 per share in cash, for a total enterprise value of approximately $5.4 billion, including debt and net of cash acquired. Cravath is representing GBT in connection with the transaction.
Deals & Cases
June 21, 2022
Convey’s $1.1 Billion Take‑Private Acquisition by TPG
On June 21, 2022, Convey Health Solutions Holdings, Inc. (“Convey”), a leading healthcare technology and services company, announced that it has entered into a definitive merger agreement pursuant to which TPG Capital, the private equity platform of global alternative asset management firm TPG and Convey’s principal shareholder, will acquire all of the outstanding shares of Convey common stock not currently owned by TPG or certain management and director shareholders for $10.50 per share in cash, representing an enterprise value of approximately $1.1 billion. Cravath is representing Convey in connection with the transaction.
